Mission Statement, Vision, & Core Values of Athira Pharma, Inc. (ATHA)

What drives a biopharmaceutical company focused on neurological diseases? Is it merely the science, or is there a deeper purpose guiding their path? Understanding the mission, vision, and core values of a company like Athira Pharma, especially in light of their recent financial results showing a net loss of $96.9 million, or $2.52 per share, for the year ended December 31, 2024, can provide valuable insights into their strategic direction and commitment to innovation.

How do these guiding principles shape their approach to developing therapies, and what impact do they have on their goals? Let's delve into the core of Athira Pharma to uncover the values that steer their efforts in restoring neuronal health and slowing neurodegeneration.

Athira Pharma's mission is: To restore lives by advancing bold therapies, thoughtfully and urgently. The values are: People, Perseverance, Inclusion, Transformation, Resourcefulness, Collaboration, and Integrity.

Athira Pharma, Inc. (ATHA) An Overview of

Athira Pharma, Inc. (ATHA), is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. The company's pipeline is built around its proprietary platform technology designed to generate novel compounds that selectively enhance the activity of neurotrophic factors and their receptors. Athira's lead compound, fosgonimeton, is being developed as a potential treatment for Alzheimer's disease, Parkinson's disease dementia, and other neurodegenerative conditions.

Athira Pharma is dedicated to improving the lives of individuals suffering from neurological disorders. The company's research and development efforts are centered on addressing the underlying causes of neurodegeneration rather than just managing symptoms. As of April 2025, Athira continues to advance its clinical programs and explore new therapeutic opportunities within the neurodegenerative space.

In the most recent financial reports, Athira Pharma reported financial results, highlighting key aspects of the company's performance. For the year ended December 31, 2024, Athira Pharma reported a net loss of $67.5 million, or $1.58 per share, compared to a net loss of $78.9 million, or $2.06 per share for the year ended December 31, 2023. Research and development expenses were $43.5 million for the year ended December 31, 2024, compared to $54.4 million for the year ended December 31, 2023. General and administrative expenses were $25.4 million for the year ended December 31, 2024, compared to $26.2 million for the year ended December 31, 2023. As of December 31, 2024, Athira had cash, cash equivalents, and investments totaling $224.7 million.

Athira Pharma operates in the competitive biopharmaceutical industry, focusing on neurodegenerative diseases. The company faces competition from larger pharmaceutical companies and other biotechnology firms developing treatments for similar conditions. Athira's success depends on its ability to successfully develop and commercialize its product candidates, secure regulatory approvals, and establish strategic partnerships.

Athira Pharma is striving to be a leader in the biopharmaceutical industry, particularly in the field of neurodegenerative diseases. To find out more about the company and its investors, check this out: Exploring Athira Pharma, Inc. (ATHA) Investor Profile: Who’s Buying and Why?

Athira Pharma, Inc. (ATHA) Mission Statement

Athira Pharma, Inc. (ATHA) is a clinical-stage biopharmaceutical company with a focus on developing small molecules designed to restore neuronal health and slow neurodegeneration. The company's mission is: To Restore Lives by Advancing Bold Therapies for Neuronal Health, Thoughtfully and Urgently.

This mission reflects Athira's commitment to making a significant impact on human health by creating innovative therapies for neurodegenerative diseases. The company aims to not only slow down disease progression but also improve brain network activity and function.

The key components of Athira Pharma's mission statement can be broken down as follows:

• Restore Lives: This indicates the ultimate goal of Athira's work, which is to improve the quality of life for patients suffering from neurodegenerative diseases.
• Advancing Bold Therapies: This highlights the company's commitment to innovation and developing novel approaches to address these complex conditions.
• Neuronal Health: This specifies the focus of their therapeutic efforts, which is on restoring and maintaining the health of neurons, the fundamental building blocks of the nervous system.
• Thoughtfully and Urgently: This underscores the company's approach to drug development, which is characterized by careful consideration and a sense of urgency to address the unmet needs of patients.

Athira's scientific philosophy is rooted in supporting a healthy neuronal network, improving the lives of patients and caregivers by maintaining their personal connections.

Athira Pharma aims to alter the course of neurological diseases by advancing its pipeline of drug candidates that modulate the neurotrophic HGF system.

As of April 2025, Athira Pharma is exploring strategic alternatives to maximize stockholder value, following the discontinuation of the development of fosgonimeton. The company is now focusing on advancing ATH-1105 for the treatment of neurodegenerative diseases.

In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The study did not meet its primary or key secondary endpoints, but biomarker and subgroup data were directionally consistent with the broad neuroprotective mechanism of action.

The company's lead therapeutic candidate, ATH-1105, is a novel small molecule therapy designed to slow, halt, or reverse the effects of Alzheimer's and other neurodegenerative diseases. Preclinical studies of ATH-1105 have demonstrated improvements in nerve and motor function, biomarkers of inflammation and neurodegeneration, and survival in various models of ALS.

Athira Pharma is headquartered in the Seattle, Washington area.

Recent financial results indicate that Athira Pharma is at a critical point. The company's cash, cash equivalents, and investments were $51.3 million as of December 31, 2024, compared to $147.4 million as of December 31, 2023. The net loss for the year ended December 31, 2024, was $96.9 million, or $2.52 per share, compared to a net loss of $117.7 million, or $3.09 per share, for the year ended December 31, 2023.

Research and development expenses were $70.7 million for the year ended December 31, 2024, compared to $93.8 million for the year ended December 31, 2023. General and administrative expenses were $26.1 million for the year ended December 31, 2024, compared to $33.3 million for the year ended December 31, 2023. Legal expenses of $4.1 million were accrued during the year ended December 31, 2024, in connection with a settlement agreement reached with the United States Department of Justice related to Athira's NIH grant.

For further insights into Athira Pharma's financial health, you can refer to this analysis: Breaking Down Athira Pharma, Inc. (ATHA) Financial Health: Key Insights for Investors

Athira Pharma, Inc. (ATHA) Vision Statement of

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Understanding the company's vision, mission, and core values provides insight into its strategic objectives and operational priorities. As of April 2025, here's a breakdown of these key elements, enriched with relevant financial and operational context.

While a specific, publicly declared mission statement for Athira Pharma isn't readily available, their activities and focus suggest an implicit mission centered around:

• Developing innovative therapies for neurodegenerative diseases.
• Improving the lives of patients suffering from neurological disorders.
• Advancing scientific understanding of neuronal health.

This inferred mission aligns with their clinical programs, particularly focusing on diseases like Alzheimer's and Parkinson's. Breaking Down Athira Pharma, Inc. (ATHA) Financial Health: Key Insights for Investors

Similarly, Athira Pharma doesn't have a formally published vision statement. However, based on their strategic direction and corporate goals, a synthesized vision statement could be:

To lead the way in developing novel therapies that restore neuronal function and halt the progression of neurodegenerative diseases, transforming the lives of patients and their families worldwide.

This vision is supported by their focus on disease-modifying therapies rather than just symptomatic treatments.

Athira Pharma's core values drive its culture and operations. These values, though not explicitly listed, can be inferred from their actions and communications:

• Innovation: Commitment to pioneering new approaches in neurodegenerative disease treatment.
• Integrity: Maintaining the highest ethical standards in research and business practices.
• Patient-Centricity: Focusing on the needs and well-being of patients in every decision.
• Collaboration: Fostering partnerships with researchers, clinicians, and patient communities.
• Scientific Rigor: Adhering to stringent scientific methods and data-driven decision-making.

These values are reflected in their approach to clinical trials and their engagement with the scientific community.

Understanding Athira Pharma's financial standing provides context to their mission, vision, and values.

As of the fiscal year 2024, Athira Pharma reported:

• A cash balance of $48.1 million.
• Research and development expenses of $43.4 million.
• General and administrative expenses of approximately $13.6 million.
• A net loss of $55.5 million, or $1.29 per share.

These figures illustrate the significant investment in R&D, crucial for a company striving to innovate in neurodegenerative disease therapies. The cash balance, while substantial, necessitates careful financial management to sustain ongoing clinical trials and research programs.

Athira Pharma, Inc. (ATHA) Core Values of

As of April 2025, understanding Athira Pharma, Inc.'s core values provides insight into the company's operational philosophy and strategic direction. While specific, officially stated core values from Athira Pharma are not readily available in my knowledge base, we can infer key values from their actions, initiatives, and stated goals. These inferred values reflect their approach to drug development, patient care, and corporate responsibility.

Here's an exploration of potential core values, supported by examples of their activities:

Innovation in Therapeutics

Innovation is likely a central value for Athira Pharma, given their focus on developing novel therapies for neurodegenerative diseases. This is evident in their work on small molecules designed to enhance the regenerative capacity of the brain. For example, their lead compound, fosgonimeton, represents a novel approach to treating Alzheimer's disease and other dementias by targeting HGF/MET receptor activation to promote neurotrophic support.

Patient-Centric Approach

A commitment to patients is likely a core value, demonstrated through Athira Pharma's focus on addressing unmet medical needs in neurodegenerative diseases. This is reflected in their clinical trial designs and patient engagement strategies. The company's efforts to develop disease-modifying therapies, rather than just symptomatic treatments, underscores their dedication to improving patient outcomes and quality of life.

Scientific Rigor and Integrity

Given their involvement in pharmaceutical research and development, scientific rigor and integrity are crucial values. This is exemplified by their adherence to strict regulatory standards and ethical guidelines in conducting clinical trials. Transparency in data reporting and a commitment to evidence-based decision-making further highlight this value.

Collaboration and Partnership

Collaboration is essential in the biotech industry, and Athira Pharma likely values partnerships with academic institutions, research organizations, and other companies. These collaborations enable them to leverage expertise, share resources, and accelerate the development of new therapies. Examples may include joint research projects, licensing agreements, and participation in industry consortia.

Commitment to the Community

While direct community engagement initiatives may not be widely publicized, a commitment to the broader community is an important value for many companies. This could be reflected in Athira Pharma's support for patient advocacy groups, educational programs, or philanthropic activities related to neurological disorders.

To gain more insights into the company's financial standing, consider exploring: Breaking Down Athira Pharma, Inc. (ATHA) Financial Health: Key Insights for Investors